NJ State Employees Deferred Compensation Plan’s Intellia Therapeutics NTLA Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,100	Closed	-$216K	–	483
2023 Q4	$216K	Hold	7,100	–	–	0.03%	422
2023 Q3	$225K	Hold	7,100	–	–	0.03%	403
2023 Q2	$290K	Hold	7,100	–	–	0.04%	380
2023 Q1	$265K	Hold	7,100	–	–	0.04%	394
2022 Q4	$248K	Hold	7,100	–	–	0.04%	393
2022 Q3	$397K	Buy	+7,100	New	+$440K	0.07%	293

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's NTLA Position: Q1 2024 in Review

NJ State Employees Deferred Compensation Plan sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 7,100 shares — an estimated $216K sold.

NJ State Employees Deferred Compensation Plan first reported a position in NTLA in Q3 2022 and held it in 6 quarters. The position peaked at $397K in Q3 2022. 285 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

NJ State Employees Deferred Compensation Plan reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 7,100 Intellia Therapeutics shares in Q1 2024, an estimated $216K.
NJ State Employees Deferred Compensation Plan first reported a position in Intellia Therapeutics in Q3 2022 and held it in 6 quarters.
NJ State Employees Deferred Compensation Plan's Intellia Therapeutics position peaked at $397K in Q3 2022.
285 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q1 2024, filed 2 May 2024.